Skip to content

Study · Randomized controlled trial · 2011

9 results

The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1.

Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S

The Journal of clinical endocrinology and metabolism2 Mar 2011Cited by 79 (Europe PMC)

PMID21367927 (opens in a new tab)DOI10.1210/jc.2010-2552 (opens in a new tab)PepBankPUB-21367927
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, N-propeptide of type I collagen rose 108% during teriparatide treatment within 6 months.

    In plain wordsIn postmenopausal women, the bone formation marker rose from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseN-propeptide of type I collagen at 6 months
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · 18 monthsAs given in this study (human).

    Measurements

    Change
    108%
    first 6 months

    Source sentences

    Summary
    In the TPD group, both N-propeptide of type I collagen and C-terminal telopeptide of type I collagen rose significantly by 108 and 175% within the first 6 months.
    1 context sentence
    Summary · context
    PATIENTS, INTERVENTION, AND OUTCOMES: Fifty-five women with postmenopausal osteoporosis were randomly allocated to treatment for 18 months with either TPD 20 μg daily or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, C-terminal telopeptide rose 175% during teriparatide treatment within 6 months.

    In plain wordsIn postmenopausal women, the bone resorption marker rose from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseC-terminal telopeptide at 6 months
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · 18 monthsAs given in this study (human).

    Measurements

    Change
    175%
    first 6 months

    Source sentences

    Summary
    In the TPD group, both N-propeptide of type I collagen and C-terminal telopeptide of type I collagen rose significantly by 108 and 175% within the first 6 months.
    1 context sentence
    Summary · context
    PATIENTS, INTERVENTION, AND OUTCOMES: Fifty-five women with postmenopausal osteoporosis were randomly allocated to treatment for 18 months with either TPD 20 μg daily or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women receiving teriparatide, N-propeptide fell 10% at month 18 compared with month 12.

    In plain wordsIn postmenopausal women receiving teriparatide, the bone formation marker fell compared with month 12.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseN-propeptide at month 18 versus month 12
    Study

    n: not reported in source

    Comparator
    Month 12
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · 18 monthsAs given in this study (human).

    Measurements

    Change vs month 12
    −10%
    teriparatide, month 18 vs month 12

    Source sentences

    Summary
    At month 18, the mean values decreased significantly compared with month 12 (-10 and -12%, respectively), but they were still significantly higher than baseline (+84 and 152%, respectively).
    2 context sentences
    Summary · context
    In the TPD group, both N-propeptide of type I collagen and C-terminal telopeptide of type I collagen rose significantly by 108 and 175% within the first 6 months.
    Summary · context
    PATIENTS, INTERVENTION, AND OUTCOMES: Fifty-five women with postmenopausal osteoporosis were randomly allocated to treatment for 18 months with either TPD 20 μg daily or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women receiving teriparatide, C-terminal telopeptide fell 12% at month 18 compared with month 12.

    In plain wordsIn postmenopausal women receiving teriparatide, the bone resorption marker fell compared with month 12.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseC-terminal telopeptide at month 18 versus month 12
    Study

    n: not reported in source

    Comparator
    Month 12
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · 18 monthsAs given in this study (human).

    Measurements

    Change vs month 12
    −12%
    teriparatide, month 18 vs month 12

    Source sentences

    Summary
    At month 18, the mean values decreased significantly compared with month 12 (-10 and -12%, respectively), but they were still significantly higher than baseline (+84 and 152%, respectively).
    2 context sentences
    Summary · context
    In the TPD group, both N-propeptide of type I collagen and C-terminal telopeptide of type I collagen rose significantly by 108 and 175% within the first 6 months.
    Summary · context
    PATIENTS, INTERVENTION, AND OUTCOMES: Fifty-five women with postmenopausal osteoporosis were randomly allocated to treatment for 18 months with either TPD 20 μg daily or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women receiving teriparatide, N-propeptide remained 84% above baseline at month 18.

    In plain wordsIn postmenopausal women receiving teriparatide, the bone formation marker remained above baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseN-propeptide at month 18 versus baseline
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · 18 monthsAs given in this study (human).

    Measurements

    Change vs baseline
    84%
    teriparatide, month 18

    Source sentences

    Summary
    At month 18, the mean values decreased significantly compared with month 12 (-10 and -12%, respectively), but they were still significantly higher than baseline (+84 and 152%, respectively).
    2 context sentences
    Summary · context
    In the TPD group, both N-propeptide of type I collagen and C-terminal telopeptide of type I collagen rose significantly by 108 and 175% within the first 6 months.
    Summary · context
    PATIENTS, INTERVENTION, AND OUTCOMES: Fifty-five women with postmenopausal osteoporosis were randomly allocated to treatment for 18 months with either TPD 20 μg daily or placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women receiving teriparatide, C-terminal telopeptide remained 152% above baseline at month 18.

    In plain wordsIn postmenopausal women receiving teriparatide, the bone resorption marker remained above baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseC-terminal telopeptide at month 18 versus baseline
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · 18 monthsAs given in this study (human).

    Measurements

    Change vs baseline
    152%
    teriparatide, month 18

    Source sentences

    Summary
    At month 18, the mean values decreased significantly compared with month 12 (-10 and -12%, respectively), but they were still significantly higher than baseline (+84 and 152%, respectively).
    2 context sentences
    Summary · context
    In the TPD group, both N-propeptide of type I collagen and C-terminal telopeptide of type I collagen rose significantly by 108 and 175% within the first 6 months.
    Summary · context
    PATIENTS, INTERVENTION, AND OUTCOMES: Fifty-five women with postmenopausal osteoporosis were randomly allocated to treatment for 18 months with either TPD 20 μg daily or placebo.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women receiving teriparatide, DKK1 did not change during the first 6 months.

    In plain wordsIn postmenopausal women receiving teriparatide, DKK1 did not change from baseline during the first 6 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeDKK1 during first 6 months
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    DKK1 did not change during the first 6 month of treatment, but only in the active group, it rose significantly at month 12 (median change +26.9%) and remained elevated at month 18 (+29.7%), at the time when the pharmacological effect of treatment with TPD appeared to be declining.
    1 context sentence
    Summary · context
    PATIENTS, INTERVENTION, AND OUTCOMES: Fifty-five women with postmenopausal osteoporosis were randomly allocated to treatment for 18 months with either TPD 20 μg daily or placebo.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, DKK1 rose 26.9% from baseline at month 12 only in the teriparatide group.

    In plain wordsIn postmenopausal women, DKK1 rose from baseline at month 12 only with teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDKK1 at month 12
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · 18 monthsAs given in this study (human).

    Measurements

    Median change
    26.9%
    teriparatide, month 12

    Source sentences

    Summary
    DKK1 did not change during the first 6 month of treatment, but only in the active group, it rose significantly at month 12 (median change +26.9%) and remained elevated at month 18 (+29.7%), at the time when the pharmacological effect of treatment with TPD appeared to be declining.
    1 context sentence
    Summary · context
    PATIENTS, INTERVENTION, AND OUTCOMES: Fifty-five women with postmenopausal osteoporosis were randomly allocated to treatment for 18 months with either TPD 20 μg daily or placebo.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women receiving teriparatide, DKK1 remained elevated by 29.7% at month 18.

    In plain wordsIn postmenopausal women receiving teriparatide, DKK1 remained above baseline at month 18.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDKK1 at month 18
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · 18 monthsAs given in this study (human).

    Measurements

    Median change
    29.7%
    teriparatide, month 18

    Source sentences

    Summary
    DKK1 did not change during the first 6 month of treatment, but only in the active group, it rose significantly at month 12 (median change +26.9%) and remained elevated at month 18 (+29.7%), at the time when the pharmacological effect of treatment with TPD appeared to be declining.
    1 context sentence
    Summary · context
    PATIENTS, INTERVENTION, AND OUTCOMES: Fifty-five women with postmenopausal osteoporosis were randomly allocated to treatment for 18 months with either TPD 20 μg daily or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.